EN
中文
EN
Who We Are
Newsroom
Innovation
Products
Investor Relations
Careers
Contact Us
Information Disclosure
Home
>
Investor Relations
>
Information Disclosure
H Share
INSIDE INFORMATION PROPOSED DISPOSAL OF A SHARES BY SHAREHOLDERS
VOLUNTARY ANNOUNCEMENT INITIATION OF PHASE III CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR DTCP INFANT
VOLUNTARY ANNOUNCEMENT FRAMEWORK AGREEMENT WITH ASTRAZENECA
Monthly Return of Equity Issuer on Movements in Securities
VOLUNTARY ANNOUNCEMENT CS-2032 ZOSTER VACCINE OBTAINS CLINICAL TRIAL APPROVAL FROM CANADA
VOLUNTARY ANNOUNCEMENT CS-2047 TETANUS VACCINE OBTAINS CLINICAL TRIAL APPROVAL
Monthly Return of Equity Issuer on Movements in Securities
POLL RESULTS OF THE 2022 ANNUAL GENERAL MEETING, THE 2023 FIRST CLASS MEETING OF A SHAREHOLDERS AND THE 2023 FIRST CLASS MEETING OF H SHAREHOLDERS
VOLUNTARY ANNOUNCEMENT MCV4 OBTAINS CLINICAL TRIAL APPROVAL
VOLUNTARY ANNOUNCEMENT TDCP ADOLESCENT AND ADULT OBTAINS CLINICAL TRIAL APPROVAL
1
15
16
17
18
19
52
津公网安备12011602300399
